GeneSystem Co

GeneSystem Co Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of GeneSystem Co (363250.KQ) as of Oct 29, 2026 is 57.58 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 82.29 % — a change of -30.04% (lower).

Cash Conversion

57.58 %

YoY

-30.04%

Last updated:

Cash Conversion Rate (OCF/Net Income) of GeneSystem Co is 2025 57.58 % . Cash Conversion Rate (OCF/Net Income) of GeneSystem Co was 2024 82.29 % . It decreases by -30.04% lower compared to the previous year.

The GeneSystem Co Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
67.87 KRW
Jan 1, 2019
51.79 KRW
Jan 1, 2020
-166.23 KRW
Jan 1, 2021
27.76 KRW
Jan 1, 2022
71.33 KRW
Jan 1, 2023
98.69 KRW
Jan 1, 2024
82.29 KRW
Jan 1, 2025
57.58 KRW
The GeneSystem Co Cash Conversion history
YEARCash ConversionYoY
57.58 %-30.04%
82.29 %-16.61%
98.69 %+38.35%
71.33 %+156.99%
27.76 %-116.70%
-166.23 %-421.00%
51.79 %-23.70%
67.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

Cash Conversion Rate (OCF/Net Income) of GeneSystem Co is 57.58 % in 2025.

Cash Conversion Rate (OCF/Net Income) of GeneSystem Co changed from 82.29 % to 57.58 %, representing a -30.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s GeneSystem Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — GeneSystem Co

All Key Metrics — GeneSystem Co